Medication info

Olmesartan Medoxomil/Rosuvastatin 20/20mg

Prescription medicationTabletOralExpired
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Korea Prime Pharmaceuticals Co., Ltd.
Appearance
White or off-white round film-coated tablets
Packaging
30 tablets/box [30 tablets (10 tablets/Alu-Alu X3)]
Approval status
Expired

MFDS item code 202003987 · Approved 2020.05.28

This product's status changed to Expired on 2025.05.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of dyslipidemia, treatment of hypertension, suppression of atherosclerotic progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil: The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose while closely monitoring their condition. Patients aged 65 years or older: No dose adjustment is necessary. Patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min): The maximum dose is 20mg once daily. Patients with mild hepatic impairment: No dose adjustment is necessary. Patients with moderate hepatic impairment: The recommended initial dose is 10mg once daily and may be increased to a maximum of 20mg daily. Patients with severe hepatic impairment: Administration of this medicine is not recommended. Rosuvastatin: Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia: The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. Elderly patients: No dose adjustment is necessary. Patients with mild or moderate renal impairment: No dose adjustment is necessary. Do not administer to patients with severe renal impairment. Special caution is required when administering 20mg of this medicine to patients with moderate renal impairment. No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. Asian patients: The recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients.
Child dose
Safety and efficacy have not been established in children under 18 years of age.

Ingredients

Manufacturer
Korea Prime Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, treatment of hypertension, suppression of atherosclerotic progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of premature coronary artery disease.
View approved original text

This medication is used for patients who need to administer both components, Olmesartan Medoxomil and Rosuvastatin, simultaneously. Olmesartan Medoxomil is effective for the treatment of essential hypertension. Rosuvastatin helps in the treatment of hypercholesterolemia and various lipid abnormalities and is used as an adjunctive therapy when dietary changes and exercise are insufficient. Additionally, it slows the progression of atherosclerosis and contributes to reducing the risk associated with cardiovascular diseases. In particular, it reduces the risk of stroke, myocardial infarction, and arterial revascularization procedures in men over 50 years and women over 60 years who have elevated high-sensitivity C-reactive protein levels and additional cardiovascular risk factors. Overall, this medication improves cardiovascular health by managing both hypertension and hyperlipidemia simultaneously.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil: The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg daily. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose while closely monitoring their condition. Patients aged 65 years or older: No dose adjustment is necessary. Patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min): The maximum dose is 20mg once daily. Patients with mild hepatic impairment: No dose adjustment is necessary. Patients with moderate hepatic impairment: The recommended initial dose is 10mg once daily and may be increased to a maximum of 20mg daily. Patients with severe hepatic impairment: Administration of this medicine is not recommended. Rosuvastatin: Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia: The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. Elderly patients: No dose adjustment is necessary. Patients with mild or moderate renal impairment: No dose adjustment is necessary. Do not administer to patients with severe renal impairment. Special caution is required when administering 20mg of this medicine to patients with moderate renal impairment. No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. Asian patients: The recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients.

Child dose

Safety and efficacy have not been established in children under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately if pregnancy is confirmed. Patients with an allergy to this medication or its components, pregnant or potentially pregnant women, and nursing mothers should not take this medication. Patients with severely impaired kidney function, biliary obstruction, severe liver dysfunction, or myopathy should also avoid this medication. Patients with low blood pressure or low body sodium levels may experience hypotension upon the initial dose, so careful monitoring is required. Patients with impaired kidney function or kidney transplant recipients should regularly check their kidney function and electrolyte levels through blood tests. This medication has the potential to cause hyperkalemia, meaning increased potassium levels, so patients with heart or kidney diseases should periodically test their potassium levels. Muscle reactions may occur; thus, if symptoms such as muscle pain, weakness, or cramps appear, the physician should be notified immediately. This medication can affect liver function, so liver function tests should be conducted before and during treatment. It is advisable to avoid alcohol consumption while taking this medication, and patients with a history of liver disease should be particularly cautious. Dizziness or drowsiness may occur, requiring caution when driving or operating dangerous machinery. This medication can interact with other drugs, so any other medications being taken must be disclosed to the physician or pharmacist. Safety and efficacy have not been established for children and adolescents under 18, hence use is not recommended. Elderly patients may have decreased bodily function; therefore, dosage adjustments and caution are necessary during treatment. Overdosing may result in symptoms such as hypotension or palpitations, and in such cases, immediate medical attention should be sought. This medication must be stored out of reach of children, and storing in other containers may alter its quality.

Side effects

Elevated ALT, elevated AST, increased serum creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, asthenia, angioedema, anaphylactic reaction, vomiting, chronic malabsorption syndrome, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional dizziness), palpitations, increased blood pressure, low back pain, increased serum creatinine, diarrhea, cough, epistaxis, upper respiratory tract infection, asthma, hypersensitivity reactions including angioedema, diabetes, headache, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia.

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture and should be kept at a temperature between 1 to 30 degrees Celsius. Storing it this way will help maintain the efficacy of the medication.

Appearance and packaging

Appearance

White or off-white round film-coated tablets

Package unit

30 tablets/box [30 tablets (10 tablets/Alu-Alu X3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.